Tested Applications
| Positive WB detected in | HeLa cells, MCF-7 cells, NCI-H1299 cells, A549 cells, 4T1 cells, SGC-7901 cells |
| Positive IHC detected in | human ovarian cancer, mouse uterus tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | MCF-7 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:2000-1:10000 |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:250-1:1000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
84046-1-RR targets HER2/ErbB2 in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
| Calculated Molecular Weight | 138 kDa |
| Observed Molecular Weight | 185 kDa |
| GenBank Accession Number | BC167147 |
| Gene Symbol | HER2/ErbB2 |
| Gene ID (NCBI) | 2064 |
| RRID | AB_3671613 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P04626 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand-binding domain and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signaling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for HER2/ErbB2 antibody 84046-1-RR | Download protocol |
| IHC protocol for HER2/ErbB2 antibody 84046-1-RR | Download protocol |
| WB protocol for HER2/ErbB2 antibody 84046-1-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The HER2/ErbB2 Recombinant monoclonal antibody (catalog number 84046-1-RR) has 1 total citation. It appears in the journal Oncogene (impact factor 9.1), in a study titled "SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer" (Liu et al., 2026). The antibody was applied in IHC and WB on human samples. The associated research field is oncology, specifically ovarian cancer and olaparib (PARP inhibitor) resistance mechanisms.
| Species | Application | Title |
|---|---|---|
Oncogene SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer.
|
